Put company on watchlist
Drägerwerk AG & Co. KGaA
ISIN: DE0005550602
WKN: 555060
About
Company Snapshot
New: Activate notification
Be informed about new publications
New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

Drägerwerk AG & Co. KGaA · ISIN: DE0005550602 · Newswire (Company)
Country: Deutschland · Primary market: Germany · EQS NID: 2126676
30 April 2025 07:30AM

Dräger with strong demand in the first quarter of 2025


EQS-News: Drägerwerk AG & Co. KGaA / Key word(s): Quarter Results/Forecast
Drägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025

30.04.2025 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Dräger with strong demand in the first quarter of 2025

  • Order intake exceeds high prior-year figure
  • Net sales close to prior-year level
  • Operating result narrowly positive

Lübeck – Drägerwerk AG & Co. KGaA increased its order intake in the first quarter of 2025 thanks to strong demand. At around EUR 861 million, order intake exceeded the high prior-year figure by around EUR 50 million (Q1 2024: EUR 810.8 million). At around EUR 730 million, net sales almost reached the prior-year level (Q1 2024: EUR 735.8 million). Earnings before interest and taxes (EBIT) amounted to EUR 0.4 million in the seasonally weak first quarter (Q1 2024: EUR 15.1 million). The EBIT margin amounted to 0.1 percent (Q1 2024: 2.0 percent).

“Measured by order volume, the first quarter of 2025 has been the best first quarter for us since the record year of 2020,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “This shows that our ‘Technology for Life’ is still very much in demand.”

Rising demand in both divisions
In the first quarter of 2025, the Group's order intake increased by 6.1 percent (net of currency effects) to EUR 860.8 million (Q1 2024: EUR 810.8 million), in particular due to the significant growth in the Europe, Middle East, and Africa (EMEA) region. Demand also increased in the Americas and Asia-Pacific (APAC) regions.

In the medical division, order intake increased by 4.2 percent (net of currency effects) to EUR 473.7 million (Q1 2024: EUR 453.7 million) following a decline in the same quarter of the prior year. This was due to higher demand in almost all product areas.

In the safety division, order intake rose by 8.4 percent (net of currency effects) to EUR 387.1 million (Q1 2024: EUR 357.2 million). The main growth driver was the Engineered Solutions area, which doubled its order volume due to high demand in almost all regions. Order intake for gas detection devices, respiratory and personal protection products and alcohol detection devices also increased significantly.

Slight decline in net sales in both divisions
Net sales in the medical division fell by 1.6 percent (net of currency effects) to EUR 413.1 million in the first quarter of 2025 (Q1 2024: EUR 417.4 million). Growth in the APAC and Germany regions was offset by a decline in the EMEA and Americas regions.

In the safety division, net sales were roughly on par with the prior-year level (Q1 2024: EUR 318.4 million) with decline of 0.6 percent (net of currency effects) to EUR 317.2 million. In the APAC region, net sales increased significantly. The Germany and Americas regions also recorded an increase in net sales. However, this was unable to compensate for the decline in the EMEA region.

Earnings positive but below prior year
The gross margin increased to 45.8 percent in the first quarter of 2025 (Q1 2024: 45.3 percent). The safety division was the margin driver with an increase of 2.2 percentage points.

Our functional expenses were 4.7 percent higher (net of currency effects) than in the same quarter of the prior year. The main reason for this was the increase in personnel expenses, partly as a result of a one-off payment for employees in Germany due to collective wage agreements.

Due to the lower net sales volume and the increase in functional expenses, EBIT amounted to EUR 0.4 million in the first quarter of 2025 and therefore fell short of the prior-year figure (Q1 2024: EUR 15.1 million). The EBIT margin amounted to 0.1 percent (Q1 2024: 2.0 percent).

Annual forecast confirmed
For the current fiscal year, Dräger continues to expect an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent. The potential impact of US customs policy on our business performance is not yet foreseeable and is therefore not included in our forecast. This also applies to the potential impact of exchange rate effects.

“The high demand for our ‘Technology for Life’ makes us confident that we will make up for the seasonal shortfall in net sales over the course of the fiscal year,” says Stefan Dräger.

Further information is available in the financial report at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.

 

Key figures for the first quarter
(€ million)
Q1 2025 Q1 2024 Change Net of cur-
rency effects
         
Order intake 860.8 810.8 +6.2 +6.1
Germany 196.4 212.1 -7.4 -7.4
Europe, Middle East, and Africa 355.3 312.0 +13.9 +13.1
Americas 172.4 160.4 +7.5 +8.7
Asia-Pacific 136.8 126.3 +8.3 +7.8
         
Order intake, medical division 473.7 453.7 +4.4 +4.2
Order intake, safety division 387.1 357.2 +8.4 +8.4
         
Net sales 730.3 735.8 -0.8 -1.2
Germany 176.6 170.0 +3.9 +3.9
Europe, Middle East, and Africa 284.4 301.8 -5.7 -6.6
Americas 150.7 156.5 -3.7 -3.7
Asia-Pacific 118.5 107.6 +10.2 +9.5
         
Net sales, medical division 413.1 417.4 -1.0 -1.6
Net sales, safety division 317.2 318.4 -0.4 -0.6
         
EBIT 0.4 15.1    
EBIT margin 0.1 2.0    
Earnings after income taxes -1.9 7.5    
         
EBIT margin, medical division -6.7 -2.7    
EBIT margin, safety division 8.9 8.3    
         
Employees 16,615 16,476    


30.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: info@draeger.com
Internet: www.draeger.com
ISIN: DE0005550602, DE0005550636 (Vorzugsaktien)
WKN: 555060, 555063 (Vorzugsaktien)
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Stuttgart, Tradegate Exchange
EQS News ID: 2126676

 
End of News EQS News Service

2126676  30.04.2025 CET/CEST

smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 02.05.2025, Calendar Week 18, 122nd day of the year, 243 days remaining until EoY.